Skip to main content

Table 1 Pathophysiological implications of TRAIL in Alzheimer’s disease

From: The immune system on the TRAIL of Alzheimer’s disease

Alzheimer’s disease model TRAIL-based treatment Main findings Reference
SH-SY5Y neuronal-like cells rTRAIL
TRAIL-neutralizing monoclonal antibody
TRAIL mediates Aβ-neurotoxicity in vitro [13]
Human AD brain / TRAIL is specifically expressed in Alzheimer’s disease brain [130]
SH-SY5Y neuronal-like cells
Primary mouse cortical neurons
anti-TRAIL-R/DR5 antibody Blockade of TRAIL-death receptor DR5 signaling prevents Aβ-neurotoxicity in vitro [133]
3xTgAD TRAIL-neutralizing monoclonal antibody Neutralization of TRAIL is associated with functional recovery, decreased Aβ burden and rebalance of both central and peripheral immune response in vivo. [17]
3xTgAD TRAIL-neutralizing monoclonal antibody Neutralization of TRAIL restrain peripheral and CNS inflammatory/immune response along with decreased microglial TNFα production, reduced accumulation of both Aβ and p-Tau protein in the hippocampus of 3xTg-AD mice. [18]
  1. Summary of the most interesting evidences of the involvement of TRAIL in the pathophysiological events related to neuroinflammatory conditions such as Alzheimer’s disease, in view of a potential future clinical development of TRAIL-based therapeutic strategies